细胞因子诱导的杀伤细胞(CIK)过继免疫治疗是肿瘤免疫治疗的一种方法，但由于常规CIK培养使用大剂量白细胞介素2(IL-2)，往往可以介导负性分子（PD-1/PD-L1）表达和抑制性Treg扩增，这可能是影响其疗效的主要原因。我们前期研究还发现常规CIK扩增还可诱导被认为与肿瘤免疫逃逸相关的ICOS+Treg。而运用本单位研制的CD40激发性抗体联合细胞因子IFN-α和IL-7体外诱导的过继免疫细胞，其CD3+CD56+NK-T细胞，中枢记忆性T细胞比例明显增加；负性共刺激分子PD-1及Treg比例下调，并且出现一群Mo-NK-DC样细胞。本研究以此为切入点，运用CD40抗体联合细胞因子IFN-α和IL-7体外制备一种新型过继免疫细胞，从细胞增殖、细胞生物学特性、细胞在体内迁移分布和细胞的体内外杀伤效应等方面探讨其与过继免疫治疗的作用及可能机制，以期为肿瘤过继免疫治疗开辟一个新的治疗方案。

Adoptive immunotherapy is a conventional method in cancer treatment after radiotherapy and chemotherapy. Cytokine induced killers cells(CIK cells) represent one of the promising adoptive cellular immunotherapy. But there are some limitations and shortcomings in traditional CIK because of a number of IL-2 were be used. We plan to evaluate a new method of adoptive immunotherapy – using antibody CD40(5C11) which prepared by our institute combined with IFN-α and IL-7 induce cells to attack tumors. Compared with the traditional CIK group, our preliminary studies suggest that the ratio of NK-T cells expressed CD3+CD56+ and the central memory T cells (TCM) were risen dramatically in our experimental group. While the ratio of negative co-stimulation molecules PD-1, induce regulatory t cells and ICOS+Treg were significantly reduce. The mechanism will be discussed in further reseach. This study will provide a new treatment for cancer adoptive immunotherapy.